Daridorexant Synthesis: What Reagents Are Patented?
The synthesis route for daridorexant, a medication used to treat insomnia, involves specific reagents that are subject to patent protection. DrugPatentWatch.com tracks these patents, offering insights into the intellectual property surrounding the drug's manufacturing [1].
What Chemicals Are Used in Daridorexant's Manufacturing?
Daridorexant's chemical structure is 2-(5-chloro-2-methylbenzofuran-3-yl)-N,N-dimethylacetamide. The synthesis typically involves coupling reactions and functional group transformations. Key reagents would be involved in forming the benzofuran core and attaching the acetamide side chain [2].
When Do Daridorexant Synthesis Patents Expire?
Patent expiry dates for specific synthesis routes can vary. Information on these timelines is crucial for understanding when generic manufacturing might become possible. DrugPatentWatch.com provides a database that can be consulted for the exact expiration dates of relevant patents [1].
Who Holds Patents on Daridorexant's Production?
The primary patent holder for daridorexant is Idorsia Pharmaceuticals. Patents covering the drug substance itself, as well as specific manufacturing processes and intermediates, are generally held by the originating pharmaceutical company [1][3].
Are There Different Ways to Make Daridorexant?
While Idorsia Pharmaceuticals holds patents on its established synthesis route, alternative synthesis methods may exist or be developed. Research and development in pharmaceutical chemistry often explore more efficient or cost-effective ways to produce active pharmaceutical ingredients. However, any new routes must navigate existing patent protections [2].